Clinical Trial

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated May 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-09-26; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2024-12-19
Trial Details
NCT Number NCT06617715
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions Pneumococcal Infectious Disease
Enrollment 3,080 participants
Start Date 2024-10-23
Primary Completion 2026-05-12 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-28